Skip to content

Income Tax at other companies

Eli Lilly logo
Eli LillyLLY
$1.45B+109%
Amgen logo
AmgenAMGN
$265M+9.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$0
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$0
Nuvation Bio logo
Nuvation BioNUVB
$0
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$1.55M+921%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%
Enterprise value$1.32B+288%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's income tax?
Bicara Therapeutics (BCAX) reported income tax of $52K in Q1 2026.
How has Bicara Therapeutics's income tax changed year-over-year?
Bicara Therapeutics's income tax decreased by 27.8% year-over-year, from $72K to $52K.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.